News
ABL Bio secures $55 million from Eli Lilly to accelerate Grabody platform development
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
- By IPP Bureau
| December 30, 2025
ABL Bio, a bispecific antibody specialist led by CEO Sang Hoon Lee, has secured a US$ 40 million upfront payment and a US$ 15 million equity investment from Eli Lilly and Company as part of a license, research, and collaboration agreement for its proprietary Grabody platform.
The two companies are already engaged in joint research and development across multiple therapeutic candidates, applying the Grabody platform to a range of modalities.
With the new funding, ABL Bio plans to ramp up research and development of its core technologies, including the Grabody bispecific antibody platform, bispecific antibody-drug conjugates (ADCs), and dual-payload ADCs.
Sang Hoon Lee, CEO of ABL Bio, said, "With the completion of the relevant administrative procedures, including the HSR Act, ABL Bio will receive the upfront payment and equity investment from Lilly.
"The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas such as obesity and muscle disorders. ABL Bio also intends to extend clinical development of its bispecific immuno-oncology candidates into combination therapies and focus on advancing next-generation ADC programs."
The agreement builds on deals signed on November 12 and 14, under which ABL Bio entered into a license, research, and collaboration agreement for the Grabody platform with Lilly valued at up to USD 2.602 billion, including the USD 40 million upfront payment, alongside a separate USD 15 million equity investment.
Through these agreements, ABL Bio aims to pursue a broad and long-term collaboration with Lilly to develop next-generation therapies.
,_Thyrocare.jpg)
